跳至主要内容
临床试验/NCT05407090
NCT05407090Unknown不适用

The Effect of Probiotic Supplementation on Systemic Inflammation and Metabolic Endotoxemia in Morbidly Obese Patients Undergoing Bariatric Surgery

Medical University of Gdansk2 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2021年8月2日最近更新:
适应症

试验速览

阶段
不适用
入组人数
80
试验地点
2
主要终点
Evaluation of changes in inflammation status

研究概览

简要总结

This study explores the effects of probiotic administration on the outcomes of surgical treatment, and also on the state of the intestinal microbiota and the intestinal barrier. The study protocol is designed as a randomized double-blind placebo-controlled clinical trial. Patients qualified for bariatric surgery will be randomized to receive probiotics or a placebo for 12 weeks. Researchers are going to evaluate changes in intestinal microbiota, epithelial permeability, weight loss, postoperative complications, and serum parameters reflecting inflammation, metabolic profile, and metabolic endotoxemia.

详细描述

The study is designed as a randomized double-blind placebo-controlled clinical trial with a 12-week probiotics intervention period. Eighty patients qualified for one of 3 types of bariatric surgery Roux-en-Y Gastric Bypass (RYGB), One-Anastomosis Gastric Bypass (OAGB), Laparoscopic Sleeve Gastrectomy (LSG) will be randomized to receive probiotics or a placebo. The time frame for the study is 6 months before and 6 months after surgery.

During this time, it is planned to collect stool samples at 5-time points: before the start of the study, before the introduction of probiotic therapy, 2 weeks before the operation, and 3 and 6 months after the operation. Collected fecal samples will be subjected to quantitative and qualitative content of the intestinal microbiota using the new generation sequencing method, as well as intestinal permeability parameters such as I-FABP (Intestinal fatty acid-binding protein), bacterial short-chain fatty acids (SCFA), and lipopolysaccharide (LPS).

Simultaneously with the collection of stool samples, an assessment of the patient's nutrition will be performed using the food frequency questionnaire (FFQ) and three-day dietary recall.

The blood samples will be collected at 4-time points: before the start of the study, before the operation, and 3 and 6 months after the operation. The following parameters will be marked in the collected blood samples: glucose, insulin, HbA1c, liver tests: ALT (Alanine transaminase), AST (Aspartate transaminase), GGTP (Gamma-glutamyl Transferase), alkaline phosphatase (ALP), bilirubin; lipid profile, CRP (C-reactive protein), total protein, albumin, inflammatory markers: IL-6, IL-10, Tumor necrosis factor-α (TNF-α), IL-8, IL-R2.

During the examination, tissue samples will be taken at 2-time points. The first is during routine gastroscopy before surgery. Gastroscopy will be performed before the inclusion of the probiotic. Duodenal and stomach biopsy will be performed during gastroscopy. The second time tissue samples will be collected intraoperatively. Gastric specimens will be collected from patients undergoing LSG. Patients qualified for RYGB and OAGB surgery will undergo gastric and jejunum biopsy. The parameters of the intestinal barrier status will be assessed in the collected tissues: Plasmalemma Vesicle-Associated Protein-1 (PLVAP-1), and Regenerating Islet Derived Protein 3 Alpha (Reg3α).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • qualification for LSG, RYGB, OAGB bariatric surgery
  • age over 18
  • written consent to participate in the study

排除标准

  • allergy/intolerance to any of the ingredients of the preparations,
  • inflammatory bowel diseases,
  • current antibiotic therapy,
  • immunosuppression,
  • biological treatment,
  • long-term antibiotic therapy,
  • taking probiotics in the 1 month prior to study enrollment,
  • neurodegenerative diseases.

结局指标

主要结局

Evaluation of changes in inflammation status

时间窗: before the intervention, 3 and 6 months after surgery

The inflammation will be assessed by measuring CRP concentration in the serum

Evaluation of changes in weight loss of the body

时间窗: 3 and 6 months after surgery

Weight loss will be measured and expressed in kilograms

次要结局

  • Evaluation of changes in the state of the intestinal microbiota - the content of intestinal microbiota(before the intervention, 2 weeks before surgery, 3 and 6 months after surgery)
  • Evaluation of changes in the state of the intestinal microbiota - the content of bacterial metabolites short-chain fatty acids (SCFA)(before intervention, 2 weeks before surgery, 3 and 6 months after surgery)
  • Evaluation of changes in the permeability of the intestinal barrier(before the intervention, 2 weeks before surgery, 3 and 6 months after surgery)
  • Evaluation of changes in the state of the intestinal barrier(before the intervention, in time of surgery)
  • Evaluation of changes in endotoxemia(before the intervention, 3 and 6 months after surgery)
  • Evaluation of changes in inflammation profile in serum(before the intervention, 3 and 6 months after surgery)
  • Evaluation of changes in intestine inflammation(before the intervention, 3 and 6 months after surgery)
  • Evaluation of changes in nutrition - frequency(before the intervention and 6 months after surgery)
  • Evaluation of changes in nutrition - quality and quantity(two weeks before surgery and 3 months after surgery)
  • Postoperative complications(During six months after surgery)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验